Empagliflozin (Jardiance) inhibits the sodium-glucose co-transporter 2 (SGLT2), which is the predominant mechanism responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin increases urinary glucose excretion.1 Empagliflozin...
Best Evidence for Clinicians: UBC Therapeutics Initiative course in Kimberley, BC WHEN: Friday, January 19 - Saturday, January 20, 2018 [Add to calendar] WHERE: Kimberley Conference & Athlete Training Centre, 290 North Star Blvd, Kimberley BC [map] Click here for more...
Evidence 101: Educational Sessions When: Wednesday, November 29 (Part 1) and Thursday, December 7 (Part 2), 2017 @ 10:00am - noon Where: MoH Conference Centre, 1515 Blanshard Street, Victoria, BC What: An educational presentation by Dr. Aaron Tejani to learn or...
Therapeutics Initiative Journal Pub Searching for Black Swans: how to think about surrogate markers in clinical drug trials When: Thursday, November 23, 2017 @ 18:00 - 21:00 h [6:00 - 9:00 pm] Where: Longwood Brew Pub (Brewmaster’s Room), Nanaimo [MAP] What: TI Journal...